$INTI
Inhibitor Therapeutics, Inc.

2015 Q2 Form 10-Q Financial Statement

#000119312515185035 Filed on May 13, 2015

View on sec.gov

Income Statement

Concept 2015 Q2 2015 Q1 2014 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $490.0K $610.0K $590.0K
YoY Change 157.89% 281.25% 195.0%
% of Gross Profit
Research & Development $300.3K $313.0K $310.0K
YoY Change -84.44% 1136.0% 1450.0%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $791.7K $922.7K $900.0K
YoY Change -62.58% 393.59% 328.57%
Operating Profit -$791.7K -$922.7K
YoY Change -62.58% 393.59%
Interest Expense $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$790.0K -$920.0K -$900.0K
YoY Change -63.08% 360.0% 309.09%
Income Tax
% Of Pretax Income
Net Earnings -$791.7K -$922.7K -$900.0K
YoY Change -63.02% 369.58% 309.09%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share $0.00 $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 211.4M shares 211.4M shares 211.4M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q2 2015 Q1 2014 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.890M $80.00K $370.0K
YoY Change 600.0%
Cash & Equivalents $1.894M $83.95K $365.2K
Short-Term Investments
Other Short-Term Assets $50.00K $43.72K $97.82K
YoY Change 70.7% 337.23%
Inventory
Prepaid Expenses $97.82K
Receivables
Other Receivables
Total Short-Term Assets $1.940M $127.7K $463.0K
YoY Change 545.5% 1121.06% 4431.45%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $250.0K $0.00
YoY Change
Total Long-Term Assets $250.0K $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $1.940M $127.7K $463.0K
Total Long-Term Assets $250.0K $0.00 $0.00
Total Assets $2.190M $127.7K $463.0K
YoY Change 628.69% 1121.06% 4431.45%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $246.5K $493.9K $325.0K
YoY Change -12.03% 39.08% 13.2%
Accrued Expenses $103.0K $23.00K
YoY Change 415.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $412.7K $568.6K $400.9K
YoY Change -9.07% -41.55% -48.34%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $412.7K $568.6K $400.9K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $412.7K $568.6K $400.9K
YoY Change -8.29% -41.38% -48.34%
SHAREHOLDERS EQUITY
Retained Earnings -$33.94M -$33.15M -$32.22M
YoY Change 10.96% 16.53% 14.07%
Common Stock $35.71M $32.70M $32.29M
YoY Change 862151.04% 1731225.3% 1709007.04%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.777M -$440.9K $62.08K
YoY Change
Total Liabilities & Shareholders Equity $2.190M $127.7K $463.0K
YoY Change 628.69% 1121.06% 4431.45%

Cashflow Statement

Concept 2015 Q2 2015 Q1 2014 Q4
OPERATING ACTIVITIES
Net Income -$791.7K -$922.7K -$900.0K
YoY Change -63.02% 369.58% 309.09%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$690.0K -$280.0K -$520.0K
YoY Change 137.93% 154.55% 205.88%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.500M 0.000 510.0K
YoY Change 346.43% -100.0% 200.0%
NET CHANGE
Cash From Operating Activities -690.0K -280.0K -520.0K
Cash From Investing Activities
Cash From Financing Activities 2.500M 0.000 510.0K
Net Change In Cash 1.810M -280.0K -10.00K
YoY Change 570.37%
FREE CASH FLOW
Cash From Operating Activities -$690.0K -$280.0K -$520.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
211419937 shares
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
456
CY2015Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
211419937 shares
CY2015Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
211419937 shares
CY2015Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
340000000 shares
CY2015Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2015Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
74689
CY2015Q1 us-gaap Liabilities Current
LiabilitiesCurrent
568566
CY2015Q1 us-gaap Common Stock Value
CommonStockValue
21142
CY2015Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
493877
CY2015Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-33145627
CY2015Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
32683593
CY2015Q1 us-gaap Stockholders Equity
StockholdersEquity
-440892
CY2015Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
127674
CY2015Q1 us-gaap Liabilities
Liabilities
568566
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
83951
CY2015Q1 us-gaap Cash Uninsured Amount
CashUninsuredAmount
0
CY2015Q1 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2015Q1 us-gaap Assets
Assets
127674
CY2015Q1 us-gaap Other Assets Current
OtherAssetsCurrent
43723
CY2015Q1 us-gaap Assets Current
AssetsCurrent
127674
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
217
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
211419937 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
211419937 shares
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
340000000 shares
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2014Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
75933
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
400899
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
21142
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
324966
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-32222953
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
32263890
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
62079
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
462978
CY2014Q4 us-gaap Liabilities
Liabilities
400899
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
365161
CY2014Q4 us-gaap Assets
Assets
462978
CY2014Q4 us-gaap Other Assets Current
OtherAssetsCurrent
97817
CY2014Q4 us-gaap Assets Current
AssetsCurrent
462978
CY2014Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
97817
CY2014Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-108505
CY2014Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
18888971 shares
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-186930
CY2014Q1 us-gaap Revenues
Revenues
0
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-196488
CY2014Q1 us-gaap Interest Expense
InterestExpense
9558
CY2014Q1 us-gaap Operating Expenses
OperatingExpenses
186930
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25325
CY2014Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
239
CY2014Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
81317
CY2014Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
108744
CY2014Q1 us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
108744
CY2014Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
161605
CY2014Q1 hppi Noncash Interest Expense
NoncashInterestExpense
6666
CY2015Q1 dei Document Type
DocumentType
10-Q
CY2015Q1 dei Entity Registrant Name
EntityRegistrantName
HedgePath Pharmaceuticals, Inc.
CY2015Q1 dei Trading Symbol
TradingSymbol
HPPI
CY2015Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P30M
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-281210
CY2015Q1 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2015Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> <i>Estimates</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> The preparation of condensed financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</p> </div>
CY2015Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
211419937 shares
CY2015Q1 dei Document Period End Date
DocumentPeriodEndDate
2015-03-31
CY2015Q1 dei Amendment Flag
AmendmentFlag
false
CY2015Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2015Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
CY2015Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001042418
CY2015Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2015Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
419703
CY2015Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-54094
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-922674
CY2015Q1 us-gaap Revenues
Revenues
0
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-922674
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
922674
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
313017
CY2015Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-281210
CY2015Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
167667
CY2015Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
609657
CY2015Q1 us-gaap Share Based Compensation
ShareBasedCompensation
419703
CY2015Q1 hppi Restricted Shares For Services Issued Period
RestrictedSharesForServicesIssuedPeriod
P5D
CY2015Q1 hppi Supply And License Agreement Term Duration From First Commercial Transaction
SupplyAndLicenseAgreementTermDurationFromFirstCommercialTransaction
P10Y

Files In Submission

Name View Source Status
0001193125-15-185035-index-headers.html Edgar Link pending
0001193125-15-185035-index.html Edgar Link pending
0001193125-15-185035.txt Edgar Link pending
0001193125-15-185035-xbrl.zip Edgar Link pending
d902877d10q.htm Edgar Link pending
d902877dex311.htm Edgar Link pending
d902877dex312.htm Edgar Link pending
d902877dex321.htm Edgar Link pending
d902877dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
hppi-20150331.xml Edgar Link completed
hppi-20150331.xsd Edgar Link pending
hppi-20150331_cal.xml Edgar Link unprocessable
hppi-20150331_def.xml Edgar Link unprocessable
hppi-20150331_lab.xml Edgar Link unprocessable
hppi-20150331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending